Literature DB >> 15757506

The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery.

M H M Yousif1, I F Benter, S Akhtar.   

Abstract

1 G-protein-coupled receptor signalling, including transactivation of receptor tyrosine kinases (RTKs), has been implicated in vascular pathology. However, the role of specific RTKs in the development of diabetes-induced cardiovascular complications is not known. 2 We investigated the ability of a chronic administration of genistein, a broad-spectrum inhibitor of tyrosine kinases (TKs), AG1478, a specific inhibitor of epidermal growth factor receptor (EGFR) TK activity, and AG825, a specific inhibitor of Erb2, to modulate the altered vasoreactivity of isolated carotid artery ring segments to common vasoconstrictors and vasodilators in streptozotocin (STZ)-induced diabetes. 3 In diabetic carotid artery, the vasoconstrictor responses induced by noradrenaline (NE), endothelin-1 (ET-1), and angiotensin II (Ang II), were significantly increased whereas vasodilator responses to carbachol and histamine were significantly reduced. Inhibition of TKs, EGFR or Erb2 pathway did not affect the body weight or agonist-induced vasoconstrictor and vasodilator responses in the non-diabetic control animals. However, inhibition of TKs by genistein, EGFR TK by AG1478 or Erb2 by AG825 treatment produced a significant normalization of the altered agonist-induced vasoconstrictor responses without affecting blood glucose levels. Treatment with diadzein, an inactive analogue of genistein, did not affect the vasoconstrictor and vasodilator responses in the diabetic animals. 4 Treatment with genistein, AG1478 or AG825 resulted in a significant improvement in diabetes-induced impairment in endothelium-dependent relaxation to carbachol and histamine. 5 These data suggest that activation of TK-mediated pathways, including EGFR TK signalling and Erb2 pathway, are involved in the development of diabetic vascular dysfunction in the carotid artery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757506     DOI: 10.1111/j.1474-8673.2004.00333.x

Source DB:  PubMed          Journal:  Auton Autacoid Pharmacol        ISSN: 1474-8665


  8 in total

1.  Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway.

Authors:  Saghir Akhtar; Mariam H M Yousif; Gursev S Dhaunsi; Bindu Chandrasekhar; Omama Al-Farsi; Ibrahim F Benter
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction.

Authors:  Saghir Akhtar; Mariam H M Yousif; Gursev S Dhaunsi; Fatma Sarkhouh; Bindu Chandrasekhar; Sreeja Attur; Ibrahim F Benter
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

Review 3.  Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease.

Authors:  Lili Sheng; George Bayliss; Shougang Zhuang
Journal:  Front Pharmacol       Date:  2021-01-26       Impact factor: 5.810

Review 4.  The epidermal growth factor receptor and its ligands in cardiovascular disease.

Authors:  Nader Makki; Kristina W Thiel; Francis J Miller
Journal:  Int J Mol Sci       Date:  2013-10-15       Impact factor: 5.923

5.  Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors.

Authors:  Eduardo Ferrero; María Dolores Mauricio; Miriam Granado; Oscar García-Villar; Martín Aldasoro; José María Vila; Manuel Hidalgo; Jorge Luis Ferrero; Nuria Fernández; Luis Monge; Angel Luis García-Villalón
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

6.  MAS-mediated antioxidant effects restore the functionality of angiotensin converting enzyme 2-angiotensin-(1-7)-MAS axis in diabetic rat carotid.

Authors:  Larissa Pernomian; Mayara Santos Gomes; Carolina Baraldi Araujo Restini; Ana Maria de Oliveira
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

7.  Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor.

Authors:  Saghir Akhtar; Bindu Chandrasekhar; Sreeja Attur; Gursev S Dhaunsi; Mariam H M Yousif; Ibrahim F Benter
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

Review 8.  Vitamin D and Its Potential Interplay With Pain Signaling Pathways.

Authors:  Abdella M Habib; Karim Nagi; Nagendra Babu Thillaiappan; VijayaKumar Sukumaran; Saghir Akhtar
Journal:  Front Immunol       Date:  2020-05-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.